Categories: AnalyticsDevelopmentDrugHealthTechPlatform
Alumis is a precision immunology company looking to eliminate the “all comer” approach that is seen with today’s treatments for people with autoimmune disease. Even with innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Alumis leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug discovery, development and immunology, in order to create medicines that change the lives of people with autoimmune disease.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.03.2024 | Series C | $259M | - |
Mentions in press and media 5
Reviews 0
